VITAMIN D IS REQUIRED FOR EFficient
|
|
- Cora Lawrence
- 6 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Occult Vitamin D Deficiency in Postmenopausal US Women With Acute Hip Meryl S. LeBoff, MD Lynn Kohlmeier, MD Shelley Hurwitz, PhD Jennifer Franklin John Wright, MD Julie Glowacki, PhD VITAMIN D IS REQUIRED FOR EFficient absorption of dietary calcium and for normal mineralization of bone. Reduction in vitamin D levels is associated with impaired calcium absorption and a compensatory increase in the level of parathyroid hormone (PTH) which, in turn, stimulates bone resorption and bone loss. According to the recent National Health and Nutrition Examination Survey Study, an estimated 26 million to 38 million US adults have osteoporosis or are at risk for osteoporosis in the hip. 1 Risk of hip fractures increases exponentially with age. Hip fractures are increasing worldwide, and are the most devastating and costly of the osteoporotic fractures. 2 Advancing age is associated with reductions in sun exposure, intake and skinactivation of vitamin D, and in vitamin D absorption, all of which may contribute to low vitamin D levels. 3 It is striking that in recent studies from England, Scotland, and South Africa, 13% to 33% of patients with hip fractures had histological signs of osteomalacia that may have been caused by prolonged vitamin D deficiency, 4-7 although not all European studies con- Context Low vitamin D levels may contribute to hip fractures in women, although limited data are available on vitamin D levels in US women admitted with acute hip fractures. Objective To determine whether postmenopausal women with hip fractures have low vitamin D and high parathyroid hormone levels compared with nonosteoporotic and osteoporotic women admitted for elective joint replacement. Design Comparative case series conducted between January 1995 and June Setting and Patients Ninety-eight postmenopausal community-dwelling women with no secondary causes of bone loss admitted for hip replacement, of whom 30 women had acute hip fractures and 68 women were admitted for elective joint replacement. Of the women admitted for elective joint replacement, 17 had osteoporosis and 51 did not. Women with comorbid conditions or who were taking medications that affect bone density and turnover were excluded. Main Outcome Measures Primary measures were levels of vitamin D and parathyroid hormone; secondary measures were body composition and markers of bone turnover. Results Women with hip fractures had lower levels of 25-hydroxyvitamin D than women without osteoporosis admitted for elective joint replacement (P =.02) and than women with osteoporosis admitted for elective joint replacement (P =.01) (medians, 32.4, 49.9, and 55.0 nmol/l, respectively; comparisons adjusted for age and estrogen intake). Parathyroid hormone levels were higher in women with fractures than women in the nonosteoporotic control group (P.001) or than elective osteoporotic women (P =.001) (medians, 5.58, 3.26, and 3.79 pmol/l, respectively; comparisons adjusted for age and estrogen intake). Fifteen patients (50.0%) with hip fractures had deficient vitamin D levels ( 30.0 nmol/l) and 11 (36.7%) had a parathyroid hormone level greater than 6.84 pmol/l. Levels of N-telopeptide, a marker of bone resorption, were greater in the women with hip fractures than in the elective nonosteoporotic controls (P =.004). Conclusions Postmenopausal community-living women who presented with hip fracture showed occult vitamin D deficiency. Repletion of vitamin D and suppression of parathyroid hormone at the time of fracture may reduce future fracture risk and facilitate hip fracture repair. Because vitamin D deficiency is preventable, heightened awareness is necessary to ensure adequate vitamin D nutrition, particularly in northern latitudes. JAMA. 1999;281: Author Affiliations: Endocrine Hypertension Division, Departments of Internal Medicine and Orthopedic Surgery, Brigham and Women s Hospital, Boston, Mass. Dr Kohlmeier is now with the Internal Medicine/Endocrinology Department, Washington Medical Group, Fremont, Calif. Financial Disclosure is listed at the end of this article. Corresponding Author and Reprints: Meryl S. Le- Boff, MD, Director of Skeletal Health and Osteoporosis Program, Endocrine-Hypertension Division, Brigham and Women s Hospital, 221 Longwood Ave, Boston, MA ( msleboff@bics.bwh.harvard.edu) American Medical Association. All rights reserved. JAMA, April 28, 1999 Vol 281, No
2 cur. 8 In the United States in 1978, Sokoloff 9 reported occult osteomalacia in 8 (25%) of 31 patients with hip fracture, and another study 10 from an elderly residential facility and hospital found 4 (12.9%) of 31 patients with osteomalacia at the time of hip fracture. Limited data are available on vitamin D status in US patients admitted for acute osteoporotic fractures. We compared such subjects with patients scheduled for elective joint replacement surgery to test the hypothesis that patients with acute hip fractures have lower vitamin D levels and higher PTH levels than do subjects without fracture with normal or even low bone mineral density. Figure 1. Selection of Postmenopausal Women Undergoing Joint Replacement Comorbid Medical Conditions (n = 190) Acute Hip (n = 262) Refused (n = 42) Postmenopausal Women (N = 805) Enrolled (n = 30) (n = 30) Comorbid Medical Conditions (n = 101) Joint Replacement (n = 543) Refused (n = 374) (n = 17) Enrolled (n = 68) Not (n = 51) Women were not included in the study if they had comorbid medical conditions or were taking medications that could affect bone, declined study participation, or had underlying hip disease other than osteoarthritis. Comorbid medical conditions included renal insufficiency, creatinine level of 177 µmol/l (0.02 mg/dl) or more, malabsorption, gastrectomy, active liver disease, acute myocardial infarction, alcoholism, and anorexia nervosa. Table 1. Patients Excluded According to Each Prespecified Exclusion Criterion No. (%) of Patients Screened (n = 389) Exclusion Criterion (n = 169) (n = 220) Excluded medication* 17 (10.1) 38 (17.3) Morbid obesity 6 (3.6) 0 (0) Rheumatic condition/underlying hip 26 (15.4) 16 (7.3) disease Dementia/unable to obtain consent 12 (7.1) 26 (11.8) Cancer within 5 y 16 (9.5) 50 (22.7) Comorbid condition 7 (4.1) 13 (5.9) Infection 0 (0) 31 (14.1) Premenopausal/perimenopausal 11 (6.5) 2 (0.9) Suppressed thyrotropin 1 (0.6) 3 (1.4) Men 1 (0.6) 0 (0) group, not osteoporotic 0 (0) 3 (1.4) Nursing home 1 (0.6) 1 (0.5) Trauma 1 (0.6) 4 (1.8) Previously enrolled 2 (1.2) 0 (0) d more than once 0 (0) 3 (1.4) Total *Glucocorticoids, androgens, anabolic steroids, anticonvulsants, calcitonin, sodium fluoride, bisphosphonates, and pharmacological doses of vitamin D ( 800 IU) were excluded because they could affect bone condition. vs fracture group, P.04. Rheumatic condition was defined as rheumatoid arthritis and ankylosing spondylitis. Underlying hip diseases other than osteoarthritis included avascular necrosis, psoriatic arthritis, and osteonecrosis. Included renal insufficiency (creatinine 1.77 µmol/l [0.02 mg/dl]), malabsorption, gastrectomy, active liver disease, acute myocardial infarction, alcoholism, and anorexia nervosa. Sex unknown prior to contact. Ineligible because residing in nursing home. METHODS Patient Recruitment A total of 805 postmenopausal women scheduled for joint replacement were identified by daily monitoring of orthopedic admissions between January 1995 and June 1998, including 262 women admitted to Brigham and Women s Hospital with acute hip fracture and 543 women scheduled for elective joint replacement either at the Brigham and Women s Hospital or the New England Baptist Hospital in Boston, Mass. Postmenopausal women who experienced either natural or surgical menopause with amenorrhea for 12 months were recruited for this study. Women receiving estrogen replacement therapy were included (46% of patients). Women were excluded if they were taking any other medications or had any disorders or abnormal admission test results that might affect bone, or had any underlying hip disease other than osteoarthritis (FIGURE 1 and TABLE 1). Of the 68 women admitted for elective joint replacement, 17 were determined to be osteoporotic (T score 2.5) according to the World Health Organization bone density criteria 11 and were analyzed separately (elective osteoporotic group) from the 51 elective patients admitted who were not osteoporotic (elective control group). There were 30 osteoporotic women with hip fractures (fracture group). Research protocols were approved by the institutional review boards of the Brigham and Women s Hospital and the New England Baptist Hospital. All patients or, if necessary, a designated family member or guardian, gave informed consent. Questionnaires Using a modification of the Nurses Health Study questionnaire 12 and dietary and detailed physical activity JAMA, April 28, 1999 Vol 281, No American Medical Association. All rights reserved.
3 questionnaires, all participants provided information regarding lifestyle, reproductive factors, dietary calcium consumption, and physical activity (TABLE 2). Spine, Proximal Femur, Total Body Bone Density, and Body Composition Bone mineral density of the spine (L1- L4), proximal femur, and total body were measured with the dual x-ray absorptiometry technique (QDR2000, Hologic Inc, Waltham, Mass). In vivo precisions (coefficient of variation percentage) in postmenopausal women for the spine, femoral neck, and trochanteric bone density measurements on different days were 1.21%, 1.74%, and 1.24%, respectively. 14 Women with vertebrae with moderately severe osteoarthritic changes, disk space narrowing, or a fracture were excluded from the analyses as these anatomic findings may elevate the spinal bone mineral density. Results were expressed as SDs and compared with bone mineral density values for age-matched healthy individuals (z score). Body composition (lean and fat mass) was determined by dual x-ray absorptiometry technique. The ratio of fat-to-lean tissue was calculated. Reproducibility of mean (SEM) for fat and lean tissue determinations in our laboratory were 1.09% (0.15%) and 0.89% (0.28%), respectively. Blood Chemistries and Assays Blood chemistries, complete blood cell counts, and tests for urinary calcium levels were performed in hospital clinical laboratories; all remaining tests were performed in the General Clinical Research Center laboratory unless otherwise specified. Blood samples were obtained preoperatively in 88% of the patients. In some instances, elective or hip fracture patients were rushed to surgery and informed consent and blood samples were obtained postoperatively. Serum intact PTH levels were measured with the sensitive Allegro immunoradiometric assay (Corning Nichols Institute, San Juan Capistrano, Calif). Serum 25-hydroxyvitamin D levels were measured using a radioimmunoassay (RIA) procedure (Incstar Corp, Stillwater, Minn) approved by the Food and Drug Administration. Levels of 1,25-dihydroxyvitamin D were measured by RIA. Urinary N-telopeptide levels, an index of bone resorption, were determined in a 24-hour urine collection by an enzyme-linked immunosorbent assay that measures cross-linked collagen peptides (Osteomark Assay, Ostex International Inc, Seattle, Wash). Bone formation markers including serum levels of osteocalcin by RIA 15 and bone-specific alkaline phosphatase (BSAP) were measured by immunoradiometric assay (Tandem-R Ostase assay, provided by Hybritech, San Diego, Calif) by Dr Gundberg of Yale University School of Medicine, New Haven, Conn. The BSAP levels were measured by immunoassay (Alphase B assay, provided, in part, by Metra Biosystems, San Diego, Calif). The interassay and intraassay coefficients of variation for all the assays ranged from 2.3% to 12.1%. Table 2. Characteristics of Enrolled Women Admitted for Surgery and Acute Hip Control (n = 51) (n = 17) (n = 30) Control vs P Value vs Variable Age, Bone, and Body Characteristics* Age, y (8.10) (10.42) (9.17) Years since menopause (9.01) (11.27) 28.0 (10.69) Bone density z score Spine (L1-L4) 1.33 (1.09) 0.33 (1.04) 0.21 (0.72) Femoral neck 1.16 (1.10) 0.32 (0.80) 0.90 (0.73) Trochanter 0.96 (1.13) 0.55 (0.74) 0.75 (1.00) Total body 1.19 (1.13) 0.87 (0.78) 0.31 (1.21) Body composition Fat g (10.04) (8.59) (10.25) % (6.28) (9.23) (10.60) Lean, g (4.02) (4.33) (6.08) Fat-lean ratio 0.95 (0.23) 0.81 (0.27) 0.56 (0.27) Intake and Activity Total calcium intake, mg/d 873 ( ) 700 ( ) 794 ( ) Alcohol, drinks per week 1 (0-14) 1 (0-10) 0 (0-16) Smoking, pack-years 8 (0-60) 0 (0-82) 8 (0-48) Physical activity, metabolic hours per week 16.4 (0-67.0) 20.2 (0-99.3) 1.5 (0-19.4) *Values measured as mean (SD) and are adjusted for estrogen intake. Bone mineral density equals SD compared with age-matched controls. Values measured as median (percentile [5th and 95th]) and adjusted for age and estrogen intake. Includes dietary and supplemental calcium. Among the elective nonosteoporotic control, elective osteoporotic, and fracture patients, 49%, 41%, and 37%, respectively, were taking a multivitamin. Metabolic hours included past and present sports, and job-related and domestic-related physical activities American Medical Association. All rights reserved. JAMA, April 28, 1999 Vol 281, No
4 Statistical Analyses Patient characteristics and markers of bone turnover were summarized as means and SDs. Analysis of variance was performed with prespecified contrasts comparing the fracture group with each of the elective groups, and having estrogen replacement therapy as a covariate. Normality tests were rejected for several calciotropic hormones, biochemical values, and baseline characteristics; therefore, medians and 5th and 95th percentiles were presented. The natural log transformed normalized intact PTH, 25- hydroxyvitamin D, N-telopeptides, BSAP (Metra Biosystems), BSAP (Hybritech), and creatinine. Analysis of variance was used for phosphate, 1,25-dihydroxyvitamin D, urinary calcium, transformed intact PTH, 25-hydroxyvitamin D, N- telopeptides, BSAP (Metra Biosystems), BSAP (Hybritech), and creatinine, with Figure 2. Women With Abnormal Parathyroid Hormone, 25-Hydroxyvitamin D, and Urinary Calcium Levels Women, % Parathyroid Hormone >6.84 pmol/l (>65 pg/ml) Group (n = 30) Group (n = 17) Control Group (n = 51) 25-Hydroxyvitamin D 30 nmol/l ( 12 ng/ml) Urinary Calcium <3 mmol/d (<120 mg/24 h) Percentage of women with elevated parathyroid hormone levels, 25-hydroxyvitamin D deficiencies and urinary calcium levels below the median. The women in the fracture group had the highest percentage of elevated parathyroid hormone levels, deficient 25- hydroxyvitamin D levels, or low-range urinary calcium concentrations. Asterisks indicate P.002 for fracture vs elective control or elective osteoporotic groups. age and estrogen replacement therapy as covariates. Cochran Mantel-Haenszel tests were used for albumin, total calcium, osteocalcin, total calcium intake, alcohol, smoking, and physical activity with estrogen replacement therapy and age above or below the median as stratification factors. Percentages and 2 tests were used to compare groups for dichotomized calciotropic hormones. Ninety-one subjects had hip surgery and 7 had knee surgery (6 from the elective control group, 1 from the elective osteoporotic group). Results were nearly identical with and without knee surgery subjects; combined results were presented. Analyses were performed using SAS software (SAS Inc, Cary, NC). RESULTS Patient Characteristics Characteristics of 98 women who were enrolled in the study are summarized in Table 2. The groups with osteoporosis (with fracture or elective) did not differ in the years since menopause, and they had comparable bone density levels (z scores) in the spine and proximal femur sites, but they differed in total body bone density. Body fat, percentage fat, and the fat-to-lean ratio showed monotonic changes among the 3 groups. Compared with the elective control group, thepostmenopausalwomenadmittedfor hip fracture had reduced exercise hours. Vitamin D and PTH Fifty percent (n = 15) of the postmenopausal women admitted with acute hip fractureshaddeficient25-hydroxyvitamin D levels ( 30.0 nmol/l [ 12 ng/ml]), 36.7% (n = 11) had elevated PTH levels ( 6.84pmol/L[ 65pg/mL]),and81.8% had urinary calcium levels below the median ( 3 mmol/d [120 mg/24 h]) (FIGURE2). Amongthewomenwithacute fracture, 8 had both deficient 25- hydroxyvitamin D levels ( 30 nmol/l) andelevatedpthlevels( 6.84pmol/L). Body Composition and Markers of Bone Turnover Circulating calcium levels were lower in the women with hip fractures than in the elective control and osteoporotic groups (TABLE 3). Compared with the women in the control group admitted for elective hip replacement, urinary N-telopeptide levels were higher in the osteoporotic elective and fracture groups (with similar z scores for the spine and hip). Levels of N- telopeptide were not different between the osteoporotic elective and fracture groups and were higher than the elective control group. Osteocalcin, BSAP (Hybritech), and BSAP (Metra Biosystems) were lower in women with fractures than in the elective osteoporotic group. The correlation between the BSAP (Hybritech) and the BSAP (Metra Biosystems) samples was 0.82 (Spearman rank correlation, P.001). Serum thyrotropin levels were comparable among the 3 groups (data not shown). There were no significant differences in calcium, albumin, phosphate, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, urinary calcium, osteocalcin, creatinine, or N-telopeptide levels between women whose serum sample was obtained preoperatively and the 12% of women whose serum sample was obtained postoperatively. COMMENT This study shows low vitamin D and high PTH levels among elderly, community-dwelling women in Boston admitted for acute hip fracture with no secondary causes of bone loss. Half had vitamin D levels in the deficient range ( 30 nmol/l) with high-range normal PTH levels or secondary hyperparathyroidism. While there is increased awareness about the importance of calcium nutrition for skeletal health, these data suggest that deficient vitamin D levels should be of concern in women admitted with hip fractures. Circulating calcium and phosphate levels were lower in women with hip fractures compared with those admitted for elective joint replacement, consistent with vitamin D deficiency, impaired calcium and phosphate absorption, and higher PTH levels. The higher PTH levels, in turn, partially 1508 JAMA, April 28, 1999 Vol 281, No American Medical Association. All rights reserved.
5 raise circulating calcium to the lower limit of the normal range and decrease the serum phosphate concentration. Low albumin levels in women with hip fractures compared with the elective groups may reflect nutritional status and are an independent predictor of vitamin D deficiency in hospitalized subjects. 16 Although we excluded patients from nursing homes and with comorbid conditions affecting bone density, it is possible that the fracture patients were more frail, had poorer nutritional status, and were exposed to less sunlight than the control group. Data were analyzed adjusting for estrogen replacement, as indicated. Estrogen can affect bone and calciotropic hormones but not 25-hydroxyvitamin D levels. Estrogen potentially can affect PTH levels, but in women who were postmenopausal for less than 20 years (as in the case, on average, for the elective subjects), PTH levels increase with age. In women with more than 20 years since menopause, similar to the women with hip fractures, estrogen may lower PTH levels. Thus, estrogen use cannot account for higher PTH levels in women with acute hip fracture compared with the elective groups. According to Khosla et al, 17 levels of vitamin D predict PTH levels regardless of estrogen therapy or menopausal status. In our study, the increase in PTH levels in postmenopausal women with hip fractures cannot be explained by differences in creatinine level; the groups were similar and no patient had a creatinine level above 159 µmol/l (1.8 mg/ dl), a level at which intact PTH levels increase to more than 6.84 pmol/l. Levels of 1,25-dihydroxyvitamin D did not differ between the women with hip fractures and those admitted for elective joint replacement. The conversion of 25-hydroxyvitamin D to 1,25- dihydroxyvitamin D in the kidney may be augmented in patients with hip fractures by the stimulatory effects of higher PTH and lower phosphate levels on renal 1-hydroxylation of vitamin D. 18 Levels of vitamin D metabolites presented herein reflect the vitamin D status at the time of hip fracture. One large study found low levels of 1,25-dihydroxyvitamin D but not 25-hydroxyvitamin D in women with hip fractures, although the vitamin D metabolites were obtained approximately 3.9 years before the fracture. 19 Others did not find low levels of 1,25-dihydroxyvitamin D in women with hip fractures after correction for a decrease in vitamin D-binding protein. Osteoporosis results from an imbalance between bone resorption and bone formation. The development of markers of bone turnover such as the urinary N-telopeptide level, which is an index of bone resorption, and serum osteocalcin and BSAP, which are bone formation markers, make it possible to estimate bone remodeling noninvasively. In our study, both the osteoporotic women admitted for elective orthopedic surgery and those with hip fractures and comparable axial bone Table 3. Calciotropic Hormones and Biochemical Values* P Value Laboratory Test Value (Normal Range for Test) No. Control Control vs vs Calcium ( mmol/l ( ) 2.39 ( ) 2.33 ( ) [ mg/dl]) [9.70 ( )] [9.55 ( )] [9.3 ( )] Albumin (37-54 g/l) (36-45) 44 (39-51) 38 (27-48) Phosphate ( mmol/l ( ) 1.36 ( ) 1.10 ( ) [ mg/dl]) [3.8 ( )] [4.2 ( )] [3.4 ( )] Intact parathyroid hormone ( ) 3.79 ( ) 5.58 ( ) ( pmol/l [10-65 pg/ml]) 25-Hydroxyvitamin D ( ( ) 55.0 ( ) 32.4 ( ) nmol/l [9-43 ng/ml]) 1,25-Dihydroxyvitamin D ( ( ) 98.8 ( ) 80.6 ( ) pmol/l [16-65 pg/ml]) Urinary calcium ( mmol/d ( ) 3.28 ( ) 2.1 ( ) [ mg/24 h]) [139.5 ( )] [131.2 ( )] [84.0 ( )] N-Telopeptides (20-76 nmol/l bone ( ) 79.0 ( ) 64.5 ( ) collagen equivalents per mmol/l creatinine) Osteocalcin (6-16 µg/l) ( ) 11.2 ( ) 4.7 ( ) Bone specific alkaline phosphatase ( ng/ml) ( ) 18.0 ( ) 16.0 ( ) ( ng/ml) ( ) 13.8 ( ) 10.4 ( ) Creatinine (61-99 µmol/l ( ) 64.8 ( ) 68.6 ( ) [ mg/dl]) [0.90 ( )] [0.85 ( )] [0.90 ( )] *Values measured as mean (percentile [5th and 95th] and adjusted for age and estrogen intake. Calcium corrected for albumin levels. Log-transformed data analyzed. Product of Metra Biosystems, San Diego, Calif. Product of Hybritech, San Diego, Calif American Medical Association. All rights reserved. JAMA, April 28, 1999 Vol 281, No
6 density and years since menopause had higher urinary N-telopeptide levels compared with the elective women without osteoporosis. Levels of N-telopeptide, osteocalcin, and BSAP increase with age and increased bone turnover is a major determinant of osteoporosis in the elderly. 20 Osteocalcin and BSAP levels were lower in the women with fractures than women with osteoporosis in the elective group. This low osteocalcin level in the women with hip fractures compared with the osteoporotic elective group, in conjunction with higher N-telopeptide levels, suggests an uncoupling of bone formation, with increased bone resorption that may be a consequence of vitamin D deficiency. Another study showed that urinary excretion of pyridinolines was higher in elderly patients with vitamin D deficiency and elevated PTH levels than in healthy young adults. 21 Studies by Akesson et al 22 showed lower osteocalcin levels and higher urinary pyridinoline levels in women with hip fractures than in age-matched controls. Several lines of evidence indicate that subclinical vitamin D deficiency may contribute to increased fractures. First, there is seasonal variation in vitamin D levels, with a decrease in winter and spring that parallels the increased hip fracture rates during those seasons. 23 Second, the increase in PTH levels due to vitamin D deficiency leads to PTHmediated bone loss. Third, vitamin D and calcium therapy reduce PTH and lead to a decrease in markers of bone resorption, thereby reducing bone breakdown 24,25 and fractures. 24,26 Low vitamin D levels and elevated PTH levels have been reported in patients with hip fractures from Europe, Scandinavia, and Australia However, in the United States, milk is fortified with vitamin D so the intake of vitamin D is greater, and vitamin D levels are higher than in Scandinavia and Europe. 30 Peacock et al 31 determined that a level of 25-hydroxyvitamin D of less than 9.98 nmol/l can cause osteomalacia. Other studies show that a level of 25-hydroxyvitamin D below 30.0 nmol/l is a threshold for decreased bone density. 32 Results may not be comparable, however, because vitamin D assays used in earlier studies from Europe and Amsterdam had lower values than the RIA assays now approved by the Food and Drug Administration and often used in the United States. 33,34 International standards for vitamin D assays and for normality are needed for application to clinical care of patients with metabolic bone disorders. The decision to treat patients with low 25-hydroxyvitamin D levels depends on the risk of a rise in PTH levels that may have deleterious effects on the skeleton. For example, PTH levels increase well before the 25-hydroxyvitamin D level decreases to 30.0 nmol/l (or 22.5 nmol/l, the lower limit of normal for some assays). A few individuals were identified with 25-hydroxyvitamin D levels between 30.0 and 54.9 nmol/l and with elevated PTH levels. According to different models, several 25-hydroxyvitamin D threshold levels for PTH have been proposed. Ooms et al 35 reported that 25-hydroxyvitamin D levels of 25.0 nmol/l are negatively related to PTH and low bone density at a cutoff of 30 nmol/l. In elderly nursing home patients including those in Boston, PTH levels were elevated with 25-hydroxyvitamin D concentrations less than 37.4 nmol/l, thus vitamin D depletion was indicated by a 25-hydroxyvitamin D level below 37.4 nmol/l. 3,36 Peacock et al 31 defined vitamin D deficiency as 25- hydroxyvitamin D levels between 9.98 and 49.9 nmol/l, when there may be mild hyperparathyroidism and decreased bone density. 31 Chapuy et al 37 studied 1569 French subjects and found that PTH levels were stable when the 25- hydroxyvitamin D level was higher than 77.4 nmol/l, using the same RIA vitamin D assay used in our study. Haden et al 38 also showed that PTH levels start to increase at 25-hydroxyvitamin D levels of less than 62.4 nmol/l. Thus, levels of 25-hydroxyvitamin D may need to be higher than 49.9 to 73.4 nmol/l to protect against secondary hyperparathyroidism. Our study was not designed to assess seasonal changes and it did not equally span all seasons in the study interval. The study may have underestimated the frequency of low vitamin D levels in women with hip fractures by excluding 190 subjects with comorbid conditions and fractures who may have had reduced sun exposure and vitamin D intake (Table 1). A recent study showed that 57% of hospitalized patients had low vitamin D levels. 16 In conclusion, this study shows occult vitamin D deficiency in postmenopausal women with hip fractures and no other secondary causes of bone loss in the northeastern United States. Correction of vitamin D deficiency or insufficiency with vitamin D supplementation or sun exposure may lead to a reduction in the exponential rise of fractures that occur with age. The new 1997 Dietary Reference Intake guidelines from the National Institutes of Health recommend 400 IU of vitamin D supplement daily for individuals from age 51 through 70 years and 600 IU daily for those older than 70 years. Supplements of about 800 IU of vitamin D per day and calcium may be necessary to attenuate bone loss in the winter and to reduce fractures. 24,26 These findings may play an important role in the orthopedic management of acute fractures in postmenopausal women. In patients with hip fractures, vitamin D repletion at the time of fracture and resultant suppression of hyperparathyroidism may facilitate hip fracture repair, implant incorporation, and reduction of future fracture risk. Vitamin D deficiency is preventable and heightened awareness is necessary to institute public health programs to ensure adequate vitamin D nutrition in the elderly, particularly in northern latitudes. Financial Disclosure: At the time of the study, Dr LeBoff served on the Scientific Advisory Board for Incstar, which manufactures a vitamin D assay, but she is no longer a member of the board. Incstar did not provide any funding for this study, and the study is not about any technology that is owned by or contractually obligated to Incstar in any way. Funding/Support: This study was supported in part by National Institutes of Health grants R01 AG and R01 AG (Drs LeBoff and Glowacki) and NCRR General Clinical Research Center to the Brigham and Women s Hospital General Clinical Research Cen JAMA, April 28, 1999 Vol 281, No American Medical Association. All rights reserved.
7 ter, and a National Osteoporosis Foundation Fellowship Award (Dr Kohlmeier). Acknowledgment: We greatly appreciate the expert assistance of Irma Sabbag and Natalie Glass and other members of the Skeletal Health and Osteoporosis Program at Brigham and Women s Hospital, and the important contributions of Clement Sledge, MD, Thomas Thornhill, MD, and Benjamin Bierbaum, MD, and the physicians in the Department of Orthopedics at Brigham and Women s Hospital and New England Baptist Hospital. We appreciate Caren Gundberg, PhD, of Yale Medical Center for her expertise with the osteocalcin and BSAP (Hybritech) assays and Beverly Potter for overseeing quality assurance of the tests in our General Clinical Research Center Laboratory. REFERENCES 1. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12: Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12: Parfitt AM, Chir B, Gallagher JC, et al. Vitamin D and bone health in the elderly. Am J Clin Nutr. 1982; 36: Aaron JE, Gallagher JC, Anderson J, et al. Frequency of osteomalacia and osteoporotic fractures of the proximal femur. Lancet. 1974;1: Chalmers J, Barclay A, Davison AM, MacLeod DAD, Williams DS. Quantitative measurements of osteoid in health and disease. Clin Orthop. 1969;63: Solomon L. of the femoral neck in the elderly: bone ageing or disease? S Afr J Surg. 1973;11: Hordon LD, Peacock M. Osteomalacia and osteoporosis in femoral neck fracture. Bone Miner. 1990; 11: Lips P, Netelenbos JC, Jongen MJM, et al. Histomorphometric profile and vitamin D status in patients with femoral neck fracture. Metab Bone Dis Rel Res. 1982;4: Sokoloff L. Occult osteomalacia in American (USA) patients with fracture of the hip. Am J Surg Pathol. 1978;2: Johnston CC, Norton J, Khairi MRA, et al. Heterogeneity of fracture syndromes in postmenopausal women. J Clin Endocrinol Metab. 1985;61: Kanis JA, for the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4: Carey VJ, Walters EE, Colditz GA, et al, for the Nurses Health Study. Body fat distribution and risk of non insulin-dependent diabetes mellitus in women. Am J Epidemiol. 1997;145: Kriska AM, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab Rev. 1992;8: El-Hajj Fuleihan G, Testa MS, Angell JE, Porrino N, LeBoff MS. Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res. 1995;10: Gundberg CM, Grant FD, Conlin PR, et al. Acute changes in serum osteocalcin during induced hypocalcemia in humans. J Clin Endocrinol Metab. 1991; 72: Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338: Khosla S, Atkinson EJ, Melton LJ III, Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population based study. J Clin Endocrinol Metab. 1997;82: Compston JE, Silver AC, Croucher PI, Brown RC, Woodhead JS. Elevated serum intact parathyroid hormone levels in elderly patients with hip fracture. Clin Endocrinol. 1989;31: Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998; 339: Garnero P, Sornay-Rendu E, Chapuy M, Delmas PD. Increased bone turnover in late menopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11: Kamel S, Brazier M, Picard C, et al. Urinary excretion of pyridinolines crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. Bone Miner. 1994;26: Akesson K, Vergnaud P, Gineyts E, Delmas PD, Obrant KJ. Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int. 1993;53: Lips P, Hackeng WHL, Jongen MJM, Van Ginkel FC, Netelenbos JC. Seasonal variation in serum concentrations of parathyroid hormone in elderly people. J Clin Endocrinol Metab. 1983;57: Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327: Prestwood KM, Pannullo AM, Kenny AM, Pillbeam CC, Raisz LG. The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int. 1996;6: Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337: Boonen S, Aerssens J, Dequeker J. Age-related endocrine deficiencies and fractures of the proximal femur, II: implications of vitamin D deficiency in the elderly. J Endocrinol. 1996;149: Harma M, Parviainen M, Koskiinen T, Voikka V, Alhava E. Bone density, histomorphometry and biochemistry in patients with fracures of the hip or spine. Ann Clin Res. 1987;19: Baker MR, McDonald H, Peacock M, Nordin BEC. Plasma 25-hydroxyvitamin D concentrations in patients with fractures of the femoral neck. BMJ. 1979; 1: McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med. 1992;93: Peacock M, Selby PL, Francis RM, Brown WB, Hordon L. Vitamin D deficiency, insufficiency, sufficiency, and intoxication, what do they mean? In: Schaefer NA, Grigoletti MG, Herrath DV, eds. Sixth Workshop on Vitamin D. Berlin, Germany: DeGruyter; 1985: Bouillon RA, Auwerx JH, Lissens WD, Pelemans WK. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr. 1987;45: Lips P, Chapuy MC, Dawson-Hughes B, Pols HAP. International comparison of serum 25-hydroxyvitamin D measurements. J Bone Miner Res. 1995;10 (suppl):s Jongen MJM, VanGinkel FC, van der Vijgh WJF, Kuiper S, Netelenbos JC, Lips P. An international comparison of vitamin D metabolite measurements. Clin Chem. 1984;30: Ooms ME, Lips P, Roos JC, et al. Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res. 1995;10: Webb A, Pillbeam C, Hanafin, Hollick M. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990;51: Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7: Haden S, Fuleihan GE, Angell JE, Cotran NM, Le- Boff MS. Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int. 1999; 64: American Medical Association. All rights reserved. JAMA, April 28, 1999 Vol 281, No
Vitamin D Status of an Outpatient Clinic Population
Calcif Tissue Int (2001) 69:263 267 DOI: 10.1007/s002230010054 2001 Springer-Verlag New York Inc. Vitamin D Status of an Outpatient Clinic Population L. Margiloff, 1 S. S. Harris, 2 S. Lee, 3 R. Lechan,
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,
More informationAnnie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu
Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationDietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites 1-3
Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites 1-3 H Karimi Kinyamu, J Christopher Gallagher, Karen A Rafferty, and Kurt E Balhorn
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationVitamin D Deficiency. Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver
Vitamin D Deficiency Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver 50 yo woman referred for osteoporosis What is striking about her
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationESPEN Congress Prague 2007
ESPEN Congress Prague 2007 Key papers in the field of nutrition Dietitian Geila S Rozen Key Papers in the field of Nutrition ESPEN 2007 Prague Geila S Rozen Clinical Nutrition Dep. Rambam health campus
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationThe Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels
CLINICAL RESEARCH STUDY The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels Walid Saliba, MD, MPH, a Ofra Barnett, PhD, a Hedy S. Rennert, MPH, a Idit Lavi, MA, a Gad Rennert, MD, PhD
More informationTestosteroneandVitaminDDeficiencyasRiskFactorsforHipFractureElderlyMalePatientsTimeforVitaminDandTestosteroneReplacement
: F Diseases Volume 16 Issue 4 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationThe New England Journal of Medicine EFFECT OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER
EFFECT OF CALCIUM AND VITAMIN D SULEMENTATION ON BONE DENSITY IN MEN AND WOMEN 65 YEARS OF AGE OR OLDER BESS DAWSON-HUGHES, M.D., SUSAN S. HARRIS, D.SC., ELIZABETH A. KRALL, H.D., AND GERARD E. DALLAL,
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOriginal Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
www.ijcem.com/ijcem807001 Original Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism Itoko Hisa 1, Hiroshi Kaji 1, Yoshifumi
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationThe Impact of Life Style & Dietary Habits on Vitamin D status Among Young Emiratis. Fatme Al Anouti, Ph.D. Zayed University, Abu Dhabi
The Impact of Life Style & Dietary Habits on Vitamin D status Among Young Emiratis Fatme Al Anouti, Ph.D. Zayed University, Abu Dhabi The Sun-Shine Vitamin Vitamin D is unique because it can be synthesized
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationAGE-RELATED HIP fracture is common in both men and
0021-972X/00/$03.00/0 Vol. 85, No. 9 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Effect of Calcium or 25OH Vitamin D 3 Dietary Supplementation
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationTHE IMPORTANCE OF ADEQUATE
ORIGINAL CONTRIBUTION Relationship Between Serum Parathyroid Hormone Levels, Vitamin D Sufficiency, and Calcium Intake Laufey Steingrimsdottir, PhD Orvar Gunnarsson, MD Olafur S. Indridason, MD, MHS Leifur
More informationBiochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3
Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1 3 Patrice Fardellone, Michel Brazier, Saïd Kamel, Jean Guéris, Anne-Marie Graulet, Jacques
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationCALCIUM INTAKE MAY be one of the many factors that
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):707 711 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1380 Lack of Effect of Calcium Intake
More informationNutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives
Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationAPPLIED NUTRITIONAL INVESTIGATION INTRODUCTION
APPLIED NUTRITIONAL INVESTIGATION Low Serum Concentrations of 25-Hydroxyvitamin D in Young Adult Japanese Women: A Cross Sectional Study Kazutoshi Nakamura, MD, MPH, Mitsue Nashimoto, BA, Shigeki Matsuyama,
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationOSTEOPOROSIS IS the most common human metabolic
JOURNAL OF BONE AND MINERAL RESEARCH Volume 16, Number 8, 2001 2001 American Society for Bone and Mineral Research Relation Between Vitamin D Insufficiency, Bone Density, and Bone Metabolism in Healthy
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationINTRODUCTION. Original Article
J Bone Metab 2015;22:135-141 http://dx.doi.org/10.11005/jbm.2015.22.3.135 pissn 2287-6375 eissn 2287-7029 Original Article Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients
More informationNIH Public Access Author Manuscript J Am Coll Nutr. Author manuscript; available in PMC 2009 August 20.
NIH Public Access Author Manuscript Published in final edited form as: J Am Coll Nutr. 2008 April ; 27(2): 274 279. Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationEarly Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
32 The Open Orthopaedics Journal, 211, 5, 32-36 Open Access Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture Hiroyuki Hashidate *,1, Mikio Kamimura 2,
More informationOriginal Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT
Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone
More informationPHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997
PHC4 Issue Brief Osteoporosis Facts and Figures November 19, 1997 Background Information: Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to
More informationIN WOMEN, serum estradiol is an important determinant
0021-972X/98/$03.00/0 Vol. 83, No. 7 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Associations between Low Levels of Serum Estradiol, Bone
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationRisedronate prevents hip fractures, but who should get therapy?
INTERPRETING KEY TRIALS CHAD L. DEAL, MD Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic THE HIP TRIAL Risedronate prevents
More informationAppropriate Goal Level for 25-Hydroxyvitamin D in Cystic Fibrosis
CHEST Appropriate Goal Level for 25-Hydroxyvitamin D in Cystic Fibrosis Original Research Natalie E. West, MD, MHS; Noah Lechtzin, MD, MHS, FCCP; Christian A. Merlo, MD, MPH; Jason B. Turowski, MD; Marsha
More informationNIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.
NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk
More informationManagement of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC
Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Learning Goals Review guidelines for osteoporosis Consider
More informationBone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date
MP 2.04.10 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationHigh Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker
J Bone Metab 214;21:189-194 http://dx.doi.org/1.115/jbm.214.21.3.189 pissn 2287-6375 eissn 2287-729 Original Article High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium
More informationGhada El-Hajj Fuleihan, MD,MPH.
Ghada El-Hajj Fuleihan, MD,MPH. Dr El-Hajj Fuleihan is Professor of Medicine and Founder and Director of the Calcium Metabolism and Osteoporosis Program at the American University of Beirut Medical Center.
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationDr Seeta Durvasula.
Dr Seeta Durvasula seeta.durvasula@sydney.edu.au 1 Avoid sun skin cancer risk Australia has highest rates of skin cancer in the world Epidemic of Vitamin D deficiency Lack of Vitamin D increases risk of
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationEfficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents
Osteoporos Int (2008) 19:663 671 DOI 10.1007/s00198-007-0465-2 ORIGINAL ARTICLE Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing
More informationVitamin D and Calcium
Vitamin D and Calcium American Association of Clinical Endocrinologists Marina Del Rey, CA September 15, 2018 Albert Shieh, MD MS Assistant Clinical Professor Department of Medicine Division of Endocrinology
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationSerum vitamin D metabolites and intestinal calcium absorption efficiency in women 1 3
See corresponding editorial on page 673. Serum vitamin D metabolites and intestinal calcium absorption efficiency in women 1 3 John F Aloia, Ding-Geng Chen, James K Yeh, and Henian Chen ABSTRACT Background:
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationThe efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial
Osteoporos Int () 4:87 877 DOI.7/s98-87-5 ORIGINAL ARTICLE The efficacy of calcium supplementation alone in elderly Thai women over a -year period: a randomized controlled trial R. Rajatanavin & L. Chailurkit
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationV t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s
Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic
More informationInfluence of vitamin D levels on bone mineral density and osteoporosis
Influence of vitamin D levels on bone mineral density and osteoporosis Mir Sadat-Ali, a Abdulmohsen H. Al Elq, b Haifa A. Al-Turki, c Fathma A. Al-Mulhim, d Amein K. Al-Ali e From the Departments of a
More informationOsteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.
Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationVitamin D Deficiency and Bone Health in Healthy Adults in Finland: Could This Be a Concern in Other Parts of Europe?
JOURNAL OF BONE AND MINERAL RESEARCH Volume 16, Number 11, 2001 2001 American Society for Bone and Mineral Research Vitamin D Deficiency and Bone Health in Healthy Adults in Finland: Could This Be a Concern
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More information